Seattle Genetics has interim data for Adcetris in cutaneous T-cell lymphoma

Seattle Genetics is announcing interim results from an investigator-sponsored phase II clinical trial of the company's lead oncology product Adcetris® (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL). The results are being announced at the T-Cell Lymphoma Forum between January 26-28, 2012 in San Francisco.

23 patients were enrolled in the phase II trial, and 17 of them had received at least two doses of the antibody drug conjugate and therefore could be evaluated. These patients were diagnosed with relapsed CD30-positive cutaneous lymphoproliferative disorders, including:

-- Lymphomatoid papulosis (LyP)
-- Primary cutaneous anaplastic large cell lymphoma (pcALCL)
-- Mycosis fungoides (MF)

Of the 17 patients, 11 of them or 65 % achieved an objective response, including seven complete remissions (CRs) and four partial remissions (PRs). Six patients had stable disease.

Source: MarketWatch

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap